Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Scagliotti GV, et al. Among authors: manegold c. J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27. J Clin Oncol. 2008. PMID: 18506025 Clinical Trial.
Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.
Scagliotti GV, Ilaria R Jr, Novello S, von Pawel J, Fischer JR, Ermisch S, de Alwis DP, Andrews J, Reck M, Crino L, Eschbach C, Manegold C. Scagliotti GV, et al. Among authors: manegold c. J Thorac Oncol. 2012 Jun;7(6):1053-7. doi: 10.1097/JTO.0b013e3182519d79. J Thorac Oncol. 2012. PMID: 22588156 Free article. Clinical Trial.
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L. Scagliotti GV, et al. Among authors: manegold c. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):690-6. Clin Cancer Res. 2005. PMID: 15701857 Clinical Trial.
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins RG, Simms L, Sugarman KP, Visseren-Grul C, Scagliotti GV. Syrigos KN, et al. Among authors: manegold c. Ann Oncol. 2010 Mar;21(3):556-561. doi: 10.1093/annonc/mdp392. Epub 2009 Oct 14. Ann Oncol. 2010. PMID: 19828561 Free article. Clinical Trial.
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV, Gridelli C, de Marinis F, Thomas M, Dediu M, Pujol JL, Manegold C, San Antonio B, Peterson PM, John W, Chouaki N, Visseren-Grul C, Paz-Ares LG. Scagliotti GV, et al. Among authors: manegold c. Lung Cancer. 2014 Sep;85(3):408-14. doi: 10.1016/j.lungcan.2014.07.005. Epub 2014 Jul 16. Lung Cancer. 2014. PMID: 25088661 Free article. Clinical Trial.
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R, Shepherd FA, De Petris L, Di Maio M, de Marinis F. Gridelli C, et al. Among authors: manegold c. Lung Cancer. 2010 Jun;68(3):319-31. doi: 10.1016/j.lungcan.2009.11.018. Epub 2009 Dec 24. Lung Cancer. 2010. PMID: 20036027 Review.
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, Lipton L, García-Sáenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I. Scagliotti GV, et al. Among authors: manegold c. J Thorac Oncol. 2012 Dec;7(12):1823-1829. doi: 10.1097/JTO.0b013e31826aec2b. J Thorac Oncol. 2012. PMID: 23154554 Free article. Clinical Trial.
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer.
Hotta K, Suzuki E, Di Maio M, Chiodini P, Fujiwara Y, Takigawa N, Ichihara E, Reck M, Manegold C, Pilz L, Hisamoto-Sato A, Tabata M, Tanimoto M, Shepherd FA, Kiura K. Hotta K, et al. Among authors: manegold c. Lung Cancer. 2013 Jan;79(1):20-6. doi: 10.1016/j.lungcan.2012.10.007. Epub 2012 Nov 17. Lung Cancer. 2013. PMID: 23164554 Review.
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Herbst RS, et al. Among authors: manegold c. J Clin Oncol. 2004 Mar 1;22(5):785-94. doi: 10.1200/JCO.2004.07.215. J Clin Oncol. 2004. PMID: 14990633 Clinical Trial.
250 results